Nektar Therapeutics Segment Reporting Other Item Amount
Nektar Therapeutics (NKTR) reported Segment Reporting Other Item Amount of $4.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-14
- Nektar Therapeutics segment reporting other item amount for the quarter ending 2026-06-30 was $4.07M, a 1.19% decline year-over-year.
- Nektar Therapeutics segment reporting other item amount for the quarter ending 2026-03-31 was $4.27M, a 4.24% decline year-over-year.
- Nektar Therapeutics segment reporting other item amount for the quarter ending 2025-12-31 was $10.93M, a 77.16% increase year-over-year.
- Nektar Therapeutics segment reporting other item amount for the quarter ending 2025-09-30 was $3.38M, a 37.23% decline year-over-year.
- Nektar Therapeutics segment reporting other item amount for fiscal 2025 was $22.88M, a 38.84% decline from fiscal 2024.
- Nektar Therapeutics segment reporting other item amount for fiscal 2024 was $37.41M, a 74.95% decline from fiscal 2023.
- Nektar Therapeutics segment reporting other item amount for fiscal 2023 was $149.34M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.07M 10-Q · filed 2026-08-14 | $8.34M 10-Q · filed 2026-08-14 | $19.27M derived: sum of 3 quarters · filed 2026-08-14 | $22.64M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.27M 10-Q · filed 2026-05-08 | $15.20M derived: sum of 2 quarters · filed 2026-05-08 | $18.58M derived: sum of 3 quarters · filed 2026-05-08 | $22.69M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $10.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $14.30M derived: sum of 2 quarters · filed 2026-03-13 | $18.42M derived: sum of 3 quarters · filed 2026-08-14 | $22.88M 10-K · filed 2026-03-13 |
| 2025-09-30 | $3.38M 10-Q · filed 2025-11-07 | $7.49M derived: sum of 2 quarters · filed 2026-08-14 | $11.95M 10-Q · filed 2025-11-07 | $18.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $4.11M 10-Q · filed 2026-08-14 | $8.57M 10-Q · filed 2026-08-14 | $14.74M derived: sum of 3 quarters · filed 2026-08-14 | $20.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.46M 10-Q · filed 2026-05-08 | $10.63M derived: sum of 2 quarters · filed 2026-05-08 | $16.01M derived: sum of 3 quarters · filed 2026-05-08 | $34.84M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $11.55M derived: sum of 2 quarters · filed 2026-03-13 | $30.38M derived: sum of 3 quarters · filed 2026-03-13 | $37.41M 10-K · filed 2026-03-13 |
| 2024-09-30 | $5.38M 10-Q · filed 2025-11-07 | $24.21M derived: sum of 2 quarters · filed 2025-11-07 | $31.24M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $18.84M 10-Q · filed 2025-08-08 | $25.86M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $7.02M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $149.34M 10-K · filed 2025-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |